Voyager Therapeutics, Inc. (VYGR) 8-K Current Report — March 9, 2026
Filed: March 9, 2026
Health Care
Biological Products, (No Diagnostic Substances)Voyager Therapeutics, Inc. (VYGR) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
Voyager Therapeutics, Inc. 8-K Mar 9, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 9, 2026 via press release (Exhibit 99.1)
- • Full financial details in Exhibit 99.1 — primary source for revenue, cash position, and pipeline spending
Get deeper insights on Voyager Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.